24 August 2020 - Submission based on the phase 3 pivotal CheckMate-9ER trial, which met its primary endpoint of significantly improving progression-free survival and secondary endpoints of overall survival and objective response rate.

Exelixis today announced the submission of a supplemental new drug application to the U.S. FDA for Cabometyx (cabozantinib) in combination with Opdivo (nivolumab) for patients with advanced renal cell carcinoma.

Read Exelixis press release